KTTA

Pasithea Therapeutics Corp

KTTA, USA

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

https://www.pasithea.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
KTTA
stock
KTTA

Pasithea Therapeutics (NASDAQ:KTTA) Upgraded at Zacks Research Defense World

Read more →
KTTA
stock
KTTA

Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ StocksToTrade

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$2

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.69

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-24.88 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-22.28 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.12

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 7.53% of the total shares of Pasithea Therapeutics Corp

1.

AdvisorShares Psychedelics ETF

(3.0793%)

since

2025/08/29

2.

AdvisorShares Investments, LLC

(2.6002%)

since

2025/06/30

3.

Citadel Advisors Llc

(0.6295%)

since

2025/06/30

4.

UBS Group AG

(0.5662%)

since

2025/06/30

5.

Fidelity Extended Market Index

(0.1977%)

since

2025/07/31

6.

LPL Financial Corp

(0.1343%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.1245%)

since

2025/07/31

8.

Hurley Capital, LLC

(0.0496%)

since

2025/06/30

9.

Spartan Total Market Index Pool G

(0.0307%)

since

2025/07/31

10.

NT Ext Equity Mkt Idx Fd - L

(0.0225%)

since

2025/06/30

11.

Northern Trust Extended Eq Market Idx

(0.0225%)

since

2025/06/30

12.

Fidelity Series Total Market Index

(0.0218%)

since

2025/07/31

13.

Tower Research Capital LLC

(0.0169%)

since

2025/06/30

14.

SBI Securities Co Ltd

(0.0141%)

since

2025/06/30

15.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0063%)

since

2025/06/30

16.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0054%)

since

2024/12/31

17.

Royal Bank of Canada

(0.0034%)

since

2025/06/30

18.

JPMorgan Chase & Co

(0.002%)

since

2025/06/30

19.

Bank of America Corp

(0.0008%)

since

2025/06/30

20.

Fidelity U.S. Equity Index Ins Trust

(0.0001%)

since

2025/07/31

21.

Citigroup Inc

(0%)

since

2025/06/30

23.

Armistice Capital, LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-06-30

EPS Actual

-0.66

EPS Estimate

0

EPS Difference

-0.66

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.